Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes
Main finding · Overall dementiaResult — go to the resultHazard ratio 0.92 95 % CI 0.89–0.95Authors' conclusion
In this large, real-world cohort, SGLT2 inhibitors demonstrated superior efficacy over GLP-1 receptor agonists in reducing the risks of overall dementia, VaD, and AD among patients with T2DM. These findings support the preferential use of SGLT2 inhibitors in mitigating dementia risk in this population, though randomized controlled trials are warranted for confirmation.
Study context
- Population
- Patients with T2D, TriNetX database221,883 matched pairs
- Exposure
- SGLT2 inhibitors vs GLP-1 receptor agonists
- Outcome
- Overall dementia incidence
Methodological detailspropensity-score matched, TriNetX database
- Propensity-score matched
- TriNetX database
Main finding
Overall dementia
Hazard ratio
0.92
95 % CI 0.89–0.95
By group
SGLT2 inhibitorsvs GLP-1 receptor agonists
HR 0.92 (95 % CI 0.89–0.95)
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
| Outcome | HR (95 % CI) | |
|---|---|---|
| VaDSGLT2ivs GLP-1 RA | 0.89 (0.84–0.95) | |
| ADSGLT2ivs GLP-1 RA | 0.90 (0.86–0.94) | |
| 0.512Hazard ratio (log scale) |
All-cause mortality
- All-cause mortality lower in the SGLT2 group (HR, 95 % CI)
- HR, 0.95; 95 % CI, 0.92-0.98
Other dementia subtypes
- No significant difference in other dementia subtypes (HR, 95 % CI)
- HR, 0.96; 95 % CI, 0.91-1.01
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in preventing Alzheimer's disease, vascular dementia, and other dementia types among patients with type 2 diabetes. Diabetes Metab. Published 12 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →